Drug Manufacturers - General Industry: Stock Analysis & Valuation
Industry: Drug Manufacturers - General | Sector: Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
The Drug Manufacturers - General industry represents a focused group of companies with highly similar business models, competitive dynamics, and market forces. This granular view makes it easier to spot which companies have sustainable competitive advantages and which are likely overvalued or undervalued.
Your Industry Knowledge = Investment Edge
If you work in Drug Manufacturers - General, follow industry news, or understand the competitive landscape, you have a significant advantage over Wall Street analysts. Use this knowledge to evaluate which companies have durable moats, realistic growth prospects, and strong margins of safety.
Drug Manufacturers - General Stocks: Value Metrics
Review the stocks in this list to compare valuations, cash flow metrics, and value investing indicators. Look for companies trading below intrinsic value with sustainable competitive advantages.
| Company | Current Price | Current Price Discount 10 years |
|---|---|---|
| Ocuphire Pharma (OCUP) |
$0.00 | none |
| Ocular Therapeutix (OCUL) |
$9.76 | none |
| Catalyst Pharmaceuticals (CPRX) |
$31.49 | none |
| Amarin Corporation plc (AMRN) |
$14.01 | none |
| AdvisorShares Vice ETF (ACT) |
$49.12 | none |
| Flexion Therapeutics (FLXN) |
$24.89 | none |
| Atossa Therapeutics (ATOS) |
$2.36 | none |
| Calithera Biosciences (CALA) |
$0.00 | none |
| Cadence Pharmaceuticals (CADX) |
$0.00 | none |
| TherapeuticsMD (TXMD) |
$2.07 | none |
| Novartis AG (NVS) |
$154.61 | none |
| Ultragenyx Pharmaceutical (RARE) |
$26.96 | none |
| Ionis Pharmaceuticals (IONS) |
$55.42 | none |
| Edge Therapeutics (EDGE) |
$51.64 | none |
| Adamis Pharmaceuticals Corporation (ADMP) |
$0.00 | none |
| Novo Nordisk A/S (NVO) |
$47.17 | none |
| Syros Pharmaceuticals (SYRS) |
$0.00 | none |
| Ironwood Pharmaceuticals (IRWD) |
$4.05 | none |
(SNTS) |
$0.00 | none |
| Xencor (XNCR) |
$21.58 | none |
| Inovio Pharmaceuticals (INO) |
$0.77 | none |
| Corbus Pharmaceuticals Holdings (CRBP) |
$9.51 | none |
| Rocket Pharmaceuticals (RCKT) |
$3.50 | none |
| Alkermes plc (ALKS) |
$49.21 | none |
| Teva Pharmaceutical Industries Limited (TEVA) |
$36.48 | none |
| LifeVantage Corporation (LFVN) |
$6.66 | none |
| OrganiGram Holdings (OGI) |
$1.23 | none |
| Bayer Aktiengesellschaft (BAYRY) |
$14.27 | none |
| Arrowhead Pharmaceuticals (ARWR) |
$89.24 | none |
| Jaguar Health (JAGX) |
$0.78 | none |
| Deciphera Pharmaceuticals (DCPH) |
$0.00 | none |
| Marinus Pharmaceuticals (MRNS) |
$0.00 | none |
| Heron Therapeutics (HRTX) |
$0.32 | none |
| KalVista Pharmaceuticals (KALV) |
$27.00 | none |
| Savara (SVRA) |
$5.57 | none |
| Veru (VERU) |
$2.79 | none |
| Viatris (VTRS) |
$16.28 | none |
| Axsome Therapeutics (AXSM) |
$215.77 | none |
| Alkermes plc ( ALKS) |
$49.21 | none |
(ALTH) |
$0.00 | none |
| Perrigo Company plc (PRGO) |
$12.85 | none |
(NBS) |
$0.00 | none |
| Imprimis Pharmaceuticals (IMMY) |
$0.00 | none |
| Aurinia Pharmaceuticals (AUPH) |
$15.37 | none |
| Johnson & Johnson (JNJ) |
$259.80 | none |
| Amylin Pharmaceuticals (AMLN) |
$0.00 | none |
| Abeona Therapeutics (ABEO) |
$7.40 | none |
(EGRX ) |
$0.25 | none |
| BioLineRx Ltd. (BLRX) |
$2.77 | none |
| SIGA Technologies (SIGA) |
$2.88 | none |
| Theravance Biopharma (TBPH) |
$16.92 | none |
| China Pharma Holdings (CPHI) |
$1.13 | none |
| Supernus Pharmaceuticals (SUPN) |
$46.88 | none |
| Bristol-Myers Squibb Company (BMY) |
$63.61 | none |
| Cara Therapeutics (CARA) |
$0.00 | none |
| Selecta Biosciences (SELB) |
$0.00 | none |
| Agios Pharmaceuticals (AGIO) |
$30.02 | none |
| Phibro Animal Health Corporation (PAHC) |
$36.33 | none |
| Cumberland Pharmaceuticals (CPIX) |
$6.68 | none |
(ABBV ) |
$250.94 | none |
| Alnylam Pharmaceuticals (ALNY) |
$286.62 | none |
| Alimera Sciences (ALIM) |
$0.00 | none |
| Pfizer (PFE) |
$25.15 | 4.9% |
| Acura Pharmaceuticals (ACUR) |
$0.00 | none |
| Abbott Laboratories (ABT) |
$108.00 | none |
| Anthera Pharmaceuticals (ANTH) |
$0.00 | none |
| Ampio Pharmaceuticals (AMPE) |
$0.18 | none |
| Affymax (AFFY) |
$0.00 | none |
Industry-Level Investment Strategy
Industry analysis allows you to compare companies operating in nearly identical markets. This granularity reveals which businesses have true competitive advantages versus those merely benefiting from industry tailwinds.
Industry Leaders
Established companies with:
- Strong brand recognition
- Pricing power
- Economies of scale
- Distribution advantages
- Customer loyalty
Often safer, but may trade at premium valuations
Niche Players
Specialists focusing on:
- Specific market segments
- Unique technologies
- Geographic advantages
- Specialized expertise
- Customer relationships
Can offer excellent value if moat is strong
Emerging Competitors
Growth companies with:
- Innovative business models
- Technology advantages
- Market share gains
- Scalable platforms
- Strong growth rates
Higher risk but potential for outsized returns
Key Questions for Drug Manufacturers - General Stocks
Competitive Analysis:
- What creates customer switching costs?
- How sustainable is the competitive moat?
- Can new entrants easily disrupt the market?
- What drives profitability differences?